QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Lahoz, A. Articles by Hall, A. PubMed PubMed Citation Articles by Lahoz, A. Articles by Hall, A. Related Content Cancer and Disease Models Related Article Social Bookmarking                   What's this?

PERSPECTIVE

DLC1: a significant GAP in the cancer genome

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA

Rho GTPases are believed to make important contributions to the development and progression of human cancer, but direct evidence in the form of somatic mutations analogous to those affecting Ras has been lacking. A recent study in Genes & Development by Xue and colleagues (1439–1444) now provides in vivo evidence that DLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung.

[Keywords: DLC1; HCC; RNAi; RhoA; mouse model]

E-MAIL halla{at}mskcc.org; FAX (212) 639-1111.

Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1691408.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma

Wen Xue, Alexander Krasnitz, Robert Lucito, Raffaella Sordella, Linda VanAelst, Carlos Cordon-Cardo, Stephan Singer, Florian Kuehnel, Michael Wigler, Scott Powers, Lars Zender, and Scott W. Lowe
Genes & Dev. 2008 22: 1439-1444. [Abstract] [Full Text] [PDF]